Table 4.
Fraction of cytoplasmic Ig-positive splenocytes in mice treated with gold and controls after 12 weeks.
| No. of pos. cIg/2 × 105 splenocytes | ||||||||
|---|---|---|---|---|---|---|---|---|
| Strain | Treatment | No. | IgG1a | IgG2a | IgG2b | IgG3 | IgM | IgE |
| A.SW | TM | 4 | 3·5 ± 1·0 | 3·0 ± 0·7 | 3·5 ± 0·6 | 9·5 ± 1·0 | 132 ± 5·6 | 0·3 ± 0·3 |
| GSTM | 4 | 14 ± 2·4b | 46 ± 5·5b | 7·3 ± 1·5 | 48 ± 5·2b | 328 ± 17b | 0·5 ± 0·3 | |
| A.TL | TM | 4 | 0·8 ± 0·3 | 0·5 ± 0·3 | 0·8 ± 0·3 | 11 ± 1·3 | 100 ± 2·5 | 0·5 ± 0·3 |
| GSTM | 4 | 1·5 ± 0·3 | 0·3 ± 0·3 | 1·8 ± 0·3 | 6·5 ± 1·0 | 100 ± 4·1 | 0·3 ± 0·3 | |
a
Numbers are mean ± s.e.m.
b
P < 0·05 significantly different from mice treated with TM (Mann-Whiney U-test). TM, treatment with a weekly intramuscular (i.m.) injection of 10·6 mg sodium thiomaleate/kg bw. Natrium aurothiomaleate (GSTM), treatment with a weekly i.m. injection of 22·5 mg sodium aurothiomaleate/kg bw.